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Tumor angiogenesis is a complex process resulting from many signals from the tumor microenvironment. From preclinical
animal models to clinical trials and practice, targeting tumors with antiangiogenic therapy remains an exciting area of study.
Althoughmanyscientiﬁcadvances havebeenachieved, leadingtothedevelopmentandclinicaluseofantiangiogenic drugssuchas
bevacizumab,sorafenib,andsunitinib,thesetherapiesfallshortoftheiranticipatedbeneﬁtsandleavemanyquestionsunanswered.
Continued research into the complex signaling cascades that promote tumor angiogenesis may yield new targets or improve upon
current therapies. In addition, the development of reliable tools to track tumor responses to antiangiogenic therapy will enable a
better understanding of current therapeutic eﬃcacy and may elucidate mechanisms to predict patient response to therapy.
1.Introduction
Angiogenesis, the formation of new blood vessels from a pre-
existing vascular network, is a crucial process during tumor
development. New vessels are needed to supply the tumor
with nutrients for sustained local growth and to enable
distant metastases [1]. The idea of tumors promoting their
own angiogenesis through the secretion of then unknown
factor(s) was ﬁrst proposed in the 1930s by Gordon Ide
[2]. In 1945, Glenn Algire [3] noticed that tumors grew
signiﬁcantly faster than normal tissues in part because of
the ability to stimulate the growth of new vessels to provide
oxygen and nutrients. In late 1960s, work by Bruce Warren,
Melvin Greenblatt and Philippe Shubik [4, 5] supported the
crucial role of tumor angiogenesis in malignant tumorige-
nesis. Their studies conﬁrmed the hypothesis that tumors
secrete soluble substances that promote vessel formation.
Folkman reported the isolation of such a substance from a
Walker 256 carcinoma grown in rats and called it a “tumor
angiogenic factor” (TAF). In 1971, Folkman proposed that
tumors cannot grow beyond a certain size without inducing
angiogenesis and proposed that inhibiting tumor angio-
genesis could prevent local tumor growth and formation
of distant metastases [6, 7]. Since then extensive research
has focused on the identiﬁcation of proangiogenic factors
produced by tumor cells and strategies to block their action.
In 2004, bevacizumab (Avastin, Genentech, Inc.) became
the ﬁrst antiangiogenic drug approved by the Food and Drug
Administration (FDA) for use in patients with metastatic
colorectal cancer [8]. Since then bevacizumab has been
approved for several other tumor types including breast,
renal cell carcinoma, nonsmall cell lung cancer (NSCLC),
and glioblastoma. Additionally, other antiangiogenic drugs
were developed, such as sunitinib malate (Sutent, Pﬁzer,
Inc.) and sorafenib tosylate (Nexavar, Bayer Pharmaceuticals
Corp.), which are FDA approved for renal cell carcinoma
and for gastrointestinal stromal tumors and hepatocellular
carcinoma, respectively. The results of the antiangiogenic
therapy in clinic have been disappointing as compared to the
promising data from preclinical animal studies. Therefore,2 Journal of Oncology
there is much to be learned about tumor angiogenesis and
how best to utilize antiangiogenic therapy. In this review
we will discuss the mechanisms of tumor angiogenesis and
clinical application of antiangiogenic therapy.
2.MolecularMechanismsof
Tumor Angiogenesis
Growing tumors secrete a number of growth factors that
can induce angiogenesis. One predominant factor that
stimulates tumor angiogenesis is vascular endothelial growth
factor A (VEGF). VEGF was initially identiﬁed as Vascular
Permeability Factor (VPF) in 1983 by Harold Dvorak and
Donald Senger in the conditioned medium of a guinea pig
cancer cell line [9]. In 1989, Napoleone Ferrara’s group
reported the isolation and sequencing of an endothelial cell
speciﬁc mitogen from pituitary cells and called it VEGF [10].
In the same issue of Science, Daniel T. Connolly reported
cloning a gene encoding VPF that turned out to be identical
with VEGF [11].
VEGF stimulates proliferation and migration of vascular
endothelial cells (ECs). It also promotes survival, inhibits
apoptosis, and regulates permeability of ECs. VEGF belongs
to a family of growth factors that includes VEGF-B, -C,
-D, -E, and placental growth factor (PlGF) [12]. Alternative
splicing of the VEGF gene results in formation of four
major isoforms of VEGF of varying molecular weights
(VEGF121,V E G F 165,V E G F 189, and VEGF206). The main
diﬀerence between these isoforms is bioavailability of VEGF
forreceptorbinding.VEGF121 existsasahighlysolublecircu-
lating form while VEGF206 remains bound exclusively to the
extracellular matrix (ECM) and is released upon proteolytic
cleavage by metalloproteinases (MMPs) or plasmin [13].
VEGF165 is the predominantly active isoform that can be
found both circulating in plasma and bound to ECM [12].
The biological functions of VEGF are mediated upon
binding to receptor tyrosine kinases Vascular Endothelial
Growth Factor Receptor-1, -2 (VEGFR1, 2). VEGFR1 binds
VEGF, VEGF-B, and PlGF [14, 15]. VEGFR1 participates
in embryonic vessel development, and is proposed to
facilitate hematopoiesis and recruitment of endothelial cell
progenitors to tumor blood vessels from bone marrow
[12]. VEGFR1 binds VEGF with high aﬃnity (KD ∼ 10–
20pM), which is signiﬁcantly stronger than the aﬃnity of
VEGF-VEGFR2interaction.Themechanismsthroughwhich
VEGFR1 functions have not been elucidated completely.
Genetic data suggest that during embryonic development
VEGFR1 functions as a negative regulator of VEGF activity.
Mice deﬁcient in VEGFR1 (e.g., VEGFR1−/−) die in utero
from an over abundance of endothelial cells that are
disorganized [16]. Furthermore, mice engineered to express
VEGFR1 lacking the tyrosine kinase domain (flt-1TK−/−)
develop normally with a fully functional vascular network
[16]. Additionally, the extent of VEGFR1 involvement in
adult angiogenesis is not well-deﬁned [17, 18]. There are
numerous reports of selective blockade of VEGFR2 activity
in tumors resulting in reduced angiogenesis and tumor
growth [19–23] suggesting that VEGFR1 activity is not
required for VEGF-induced angiogenesis in pathological
conditions. However, the function of VEGFR2 is deﬁned
more clearly.
VEGFR2 is the key mediator of VEGF-driven angiogene-
sis. VEGFR2 is crucial during embryonic vascular develop-
ment. Heterozygous and homozygous VEGFR-2 knockout
mice die in utero due to disrupted vasculogenesis and
hematopoiesis [24]. Upon VEGF binding, VEGFR2 under-
goes auto-transphosphorylation and downstream eﬀectors
including phospholipase C gamma, protein kinase C, Raf,
the MAP kinase signaling cascades, and the PI3K and
FAK pathways are activated, leading to endothelial cell
proliferation, migration, and survival (Figure 1)[ 25, 26].
VEGFR3 binds VEGF-C and -D and is directly involved
in formation of the lymphatic vasculature physiologic and
tumor development [27, 28]. There is also experimental
evidence that VEGFR3 mediated activation of lymphatic
endothelial cells is crucial for metastasis [29]. Neuropilin-1
(Nrp-1) and Neuropilin-2 (Nrp-2) are coreceptors originally
identiﬁed for their involvement in neuronal guidance, and
that bind members of collapsin/semaphorin protein family
[30]. The Nrps can also bind to certain heparin binding
isofoms of VEGF (e.g., VEGF165) to enhance the binding of
VEGF to VEGFR1, and VEGFR2 (Figure 1)[ 31, 32]. Nrps
lack tyrosine kinase domains but do contain an intracellular
PDZ domain, which has been suggested to facilitate VEGF
speciﬁc signaling.
VEGF expression within tumors is regulated by oxygen
levels, growth factors and cytokines, and oncogene acti-
vation/tumor suppressor inactivation [26]. Hypoxia in the
tumor microenvironment is one of the most important
factors inﬂuencing expression of VEGF. Hypoxia inducible
factor-1 (HIF-1) is a transcription factor that regulates
expression of certain genes in response to intracellular
oxygen levels [33, 34]. It consists of two subunits: alpha
(α) and beta (β). Normoxic conditions favor ubiquitin-
dependent proteosome-mediated degradation of HIF-1α
subunit, while oxygen deprivation stabilizes and enhances
HIF-1α/HIF-1β dimerization. These dimers interact with a
hypoxia response element (HRE) in the promoter region
of many genes, including VEGF [35–37]. VEGF expression
is also regulated via paracrine or autocrine release of
growth factors and cytokines such as platelet-derived growth
factor (PDGF), epidermal growth factor (EGF), keratinocyte
growthfactor,insulin-likegrowthfactor(IGF),transforming
growth factors alpha and beta (TGF-α,- β), interleukin
1α and 6 (IL-1α, -6) and prostaglandins (PGE2) [38–43].
During tumorigenesis, certain genetic mutations in the
ras oncogene or Wnt-signaling pathways may also lead to
elevated expression of VEGF [44, 45]. Tumor-derived VEGF
mayalsofunctioninanautocrinemanner[46].Receptorsfor
VEGF (e.g., VEGFR1, VEGF2, Nrp1, Nrp2) are expressed on
multiple cancer cell lines [47, 48], and there is evidence that
VEGF can function as a cell survival factor for tumor cells
and vascular endothelial cells within the tumor [49, 50].
The idea of vascular progenitor cells derived from bone
marrow that incorporate into the tumor vasculature is
exciting and controversial [51]. Circulating VEGF as well
as other growth factors produced by tumor can mobilize
variety of hematopoietic cell populations that express CD45,Journal of Oncology 3
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Figure 1: VEGF signaling interactions. The VEGF family can bind to VEGFR1, VEGFR2, and VEGFR3 inducing signaling cascades to
promote vasculogenesis, angiogenesis, and lymphangiogenesis, respectively.
VEGFR1, VEGFR2, VE-cadherin, tie-2 or CXC chemokine
receptor 4 [52–56]. There is a signiﬁcant discrepancy among
the published studies regarding the percentage contribution
of bone marrow-derived cells into the formation of tumor
vasculature—numbers vary between as high as 50% to as
low as 5% [52, 57–59]. However, Robert Kerbel’s group
observed that after exposure to chemotherapy or vascular
disrupting agents (VDAs), there is a signiﬁcant eﬄux of
circulating bone marrow-derived cells (BMDC) homing to
the sites of tumor vasculature [60, 61]. This phenomenon
may havea potent clinical application if conﬁrmed in human
studies.UsingagentsthatcanblockincorporationofBMDCs
may contribute to better outcomes of chemotherapy by
interfering with tumor angiogenesis.
3. ClinicalApplications of
Antiangiogenic Therapy
TheVEGFpathwaycanbetargetedtherapeuticallyatvarious
molecular levels. Currently two major concepts are studied
in the clinical setting: blocking VEGF from binding to its
extracellular receptors with VEGF antagonists (antibodies,
VEGF-Trap) or inhibiting VEGF signaling with tyrosine
kinase inhibitors (TKIs) [62]. As previously mentioned,
bevacizumab is a humanized, VEGF-neutralizing antibody
that was the ﬁrst antiangiogenic agent approved by the
FDA for use in cancer patients. In 2004, a pivotal phase
III clinical trial demonstrated a 4.6 months survival beneﬁt
of adding bevacizumab to chemotherapy in patients with
metastatic colorectal cancer [8]. After the encouraging data
from this trial were published, patients with other solid
malignancies were enrolled into a multitude of clinical trials
that added bevacizumab into the standard treatment of
care. However, the results from many of these clinical trials
are disappointing. Most patients fail to achieve long-term
beneﬁts with bevacizumab plus chemotherapy [63]. Selected
groups of patients respond with tumor shrinkage, disease
stabilization, or improvements in survival that are counted
in months rather than years [64].
A new approach to anti-VEGF therapy currently being
evaluated is genetically engineered fusion proteins that
function as molecular “traps” for VEGF. Aﬂibercept (VEGF-
Trap, Regeneron Pharmaceuticals, Inc.) is a recombinant
fusion protein that binds both VEGF and PlGF with high
aﬃnity. It is composed of the extracellular domains of
VEGFR1 and VEGFR2 that are fused to the Fc region of4 Journal of Oncology
human IgG [65]. Currently, there are more than 40 ongoing
trials (http://clinicaltrials.gov/) that explore this therapy in
solid and hematologic malignancies.
Small molecule TKIs with antiangiogenic activity are
another important area of active clinical research. Unlike
monoclonalantibodies(i.e.,bevacizumab)orfusionproteins
(i.e., aﬂibercept), TKIs are small molecules that interfere
directly with tyrosine kinase activity (Figure 2). Since the
intracellular domain targeted by TKIs is structurally similar
in many tyrosine kinase receptors, a single TKI usually inter-
feres with the activity of multiple receptors [66]. Sunitinib
and sorafenib are multitargeting TKIs that can block activity
angiogenic targets such as of VEGFR1, 2, 3, platelet-derived
growth factor (PDGF) receptors and c-Kit or RET. After con-
ﬁrmed clinical beneﬁt for sunitinib and sorafenib in selected
patient groups [67, 68], there are now a variety of ongoing
clinical trials recruiting patients from a broad spectrum of
solid malignancies (http://www.clinicaltrials.gov/).
4. Mechanisms of Action of
Antiangiogenic Agents
Various agents that target tumor angiogenesis are currently
under investigation in diﬀerent cancer types in many clinical
trials [62]. While some of these agents show more encour-
aging results than the others, a common clinical problem
is the lack of eﬀective tools to monitor tumor response to
these novel therapies [69]. The Response Evaluation Criteria
in Solid Tumors (RECIST) criteria that are commonly used
to monitor tumor response may not be an eﬀective or even
accurate measure of response to antiangiogenic agents. As an
example,antiangiogenicagentswilloftenenhancethecentral
necrosis of tumors without changing the overall tumor size,
which is a central parameter in RECIST evaluation [70].
An area of intense debate is how antiangiogenic agents
actually work in terms of combating cancer [71]. According
to the Folkman hypothesis, interference with tumor angio-
genesis results in either inhibition of new vessel formation
or progressive loss of existing vessels supporting tumor
growth.Aninadequatebloodsupplycausedbyareductionof
the vascular network in response to antiangiogenic therapy,
slows and eventually prevents tumor growth and causes the
tumor to regress to a “state of dormancy”, which can be
clinically undetectable [7]. Evidence for this paradigm can
be found in preclinical studies where fast-growing human
tumors are treated with anti-VEGF therapy for long periods
of time [72, 73].
An alternative explanation for anti-VEGF activity and
possibly antiangiogenic agents in general is anchored in the
heterogeneity of tumor vasculature. A minority of tumor
blood vessels are associated intimately with pericytes and
as a result are more functional and stable [74]. These
vessels are not as dependent on VEGF stimulation for
survival. In contrast, a large proportion of tumor blood
vessels are tortuous, leaky, and immature, lacking interac-
tions with pericytes. Furthermore, these vessels are more
dependent on survival signals provided by VEGF and other
growth factors. When VEGF levels are decreased via therapy
these vessels regress, leaving behind a more stable vascular
network. There is also compelling evidence that VEGF
actively suppresses pericyte recruitment, therefore blocking
VEGF activity may also result in the active recruitment of
pericytes to remaining blood vessels [75]. As a result, the
vasculature that remains in the face of anti-VEGF therapy
consists of a higher percentage of pericyte associated blood
vessels that are more eﬃcient in function. This process has
been termed “normalization” by Jain who hypothesizes that
anti-VEGF therapy actually “normalizes” tumor vasculature
and transiently improves blood ﬂow within the tumor,
thus enhancing the delivery of chemotherapy [76, 77].
Additionally, because stable vessels within the tumor are
less leaky, interstitial pressure may decrease and thereby
facilitate tissue penetration of chemotherapy. A supportive
corollary to this is that antiangiogenic therapy has been
shown to increase the eﬃcacy of radiation therapy due to
transient improvement in tumor oxygenation as a result
of antiangiogenic treatment and vascular normalization
[71, 78].
5. MonitoringClinicalResponse to
Antiangiogenic Therapies
The majority of noninvasive techniques used to assess the
eﬀects of antiangiogenic therapy do not directly visualize
tumor blood vessels. Rather surrogate markers for vascular
function such as blood ﬂow are used commonly. These tech-
niques rely on the fact that during the course of treatment
blood ﬂow within the tumor changes, either increasing due
to normalization or decreasing due to diminished blood
supplyandvesselregression[79–81].Hemodynamicchanges
within the tumor vasculature remain the major surrogate
markers for majority of these techniques. Clinically relevant
imaging techniques include magnetic resonance imaging
(MRI), computed tomography (CT), positron emission
tomography (PET), and ultrasound (US). Each of these
techniques can be used with appropriate contrast media
to evaluate hemodynamic function within tissues including
solid tumors.
Perfusion dynamic contrast-enhanced (DCE) MRI has
been used successfully in both preclinical and clinical models
to follow hemodynamic function [82]. DCE-MRI makes
use of paramagnetic tracers, mostly consisting of a low-
molecular-weight gadolinium (Gd) and is the standard
method for measurement of vascular function in clinical
trials of antiangiogenic drugs [83]. Signal enhancement
obtained by DCE-MRI depends on tissue perfusion and per-
meability, contrast concentration, and extravascular space
volume [84]. DCE-MRI has been especially useful in clinical
studies of patients with liver and brain tumors [85–90],
and has been investigated as a possible pharmacodynamic
biomarker sorafenib therapy in metastatic renal carcinoma
[91].
CT-based perfusion imaging techniques are also used
to assess the vascular eﬀects of antiangiogenic treatments
[92, 93]. Although DCE-MRI gives better spatial resolution
and is a superior method for brain imaging studies, CT still
remains a preferred method for imaging structures within
the thorax, abdomen, and pelvis. Thus some clinical studiesJournal of Oncology 5
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Figure 2: Inhibition of VEGF signaling pathways. Several classes of drugs have been developed to combat VEGF-mediated tumor
angiogenesis. Monoclonal anti-VEGF antibodies (e.g., bevacizumab) and soluble receptor constructs (e.g., VEGF-Trap) bind to the
VEGF and PlGF preventing their interaction and signaling through VEGFR1 and VEGFR2. Tyrosine kinase inhibitors (TKIs) inhibit the
intracellular tyrosine kinase activity of VEGF receptors, blocking downstream signaling.
investigating antiangiogenic agents have used perfusion
CT rather than DCE-MRI to evaluate tumor blood ﬂow
[94–96].
In addition, PET-based imaging techniques are widely
used in clinical oncology [97]. PET uses positron-emitting
tracers,ofwhichH15
2 Ocanbeusedtostudytumorbloodﬂow
and this method has been used in clinical trials with good
results [98]. H15
2 O is a positron-emitting tracer that can dif-
fusefreelyintothetissuesanditstissueuptakecorrelateswith
blood perfusion [99]. Both H15
2 O PET and DCE-MRI are
useful for monitoring tumor microvasculature. H15
2 OP E Ti s
particularlyusefulintheassessmentoftissueperfusionwhile
DCE-MRI measures also vascular permeability. A major
disadvantage of both methods is their limited availability for
patients because they require highly skilled and trained staﬀ,
that is, typically only available in large radiology or nuclear
medicine departments.
Worldwide, ultrasound (US) is one of the most com-
monly used noninvasive imaging techniques. It provides
anatomical information and can also be used to assess
physiological function (e.g., blood ﬂow with doppler ultra-
sound) or to serve as a therapeutic tool (e.g., high frequency
ultrasound ablation of the tissue) [100, 101]. Because blood
is only slightly less echogenic than surrounding tissue,
US is not very eﬀective for imaging small blood vessels.
However, the introduction of US contrast agents expanded
the clinical and research applications of US especially in
the area of vascular imaging. Microbubbles (MB) are small
particles (1–10μm) consisting of a gaseous core and a shell
of protein (e.g., albumin) or lipid mixture [102] that can
be injected intravenously and are promising US contrast
agents. MBs are intravascular tracers that do not extravasate
unless there is structural damage to the vessel wall. When
injected intravenously, MBs enhance the echogenicity of the
blood pool and enable distinction of vascular structures
from the surrounding tissue. Within in an ultrasound
ﬁeld MB resonate in response to the ultrasound wave and
can enhance both grey scale images and ﬂow mediated
doppler signals. Their high echogenic properties are due
to the diﬀerence of compressibility of the gaseous core
within the MB and the surrounding blood components
and tissue [103]. MB have proven their usefulness in
clinical echocardiography, especially in the evaluation of
systolic myocardial function, ejection fraction, delineating
endocardial border, and myocardial blood ﬂow [104–106].
Imaging metastatic deposits or primary liver tumors (e.g.,
hepatocellular carcinoma) with contrast US is an example
of the clinical application for MB-enhanced US imaging
[107, 108]. The liver is one of the organs, that is, most
commonlyaﬀectedbydistantmetastases,andearlydetection
of small (subcentimeter) lesions by contrast-enhanced US
is of clinical signiﬁcance [109–111]. Comparative studies of
the sensitivity and speciﬁcity of PET, CT, DCE-MRI, and
MB-enhanced US for detection of tumor perfusion showed6 Journal of Oncology
t h a tc o n t r a s tU Si sa ne ﬀective and correlative method with
signiﬁcant clinical potential [112, 113].
MB behave hemodynamically like red blood cells, cir-
culate freely after injection and are small enough to reach
the capillary microcirculation [114] .T h ei d e ao ft a r g e t e d
imaging using contrast US is based on the selective accumu-
lation of MB in speciﬁc vascular beds that can be reached
by US wave and subsequently imaged. MB with an albumin-
containing shell can adhere to endothelial cells that are
activatedbyinﬂammatorycytokines,oractivatedleukocytes,
which enables MB to be targeted passively to the areas of
vascular inﬂammation [115–117]. MB can be also targeted
actively to speciﬁc vascular beds by conjugation of targeting
moieties (e.g., antibodies or peptides) to the MB shell [118–
120]. In preclinical studies, MB have been targeted to various
endothelial markers expressed on inﬂamed or ischemic
tissues such as the myocardium or kidney [121–123].
Although tumor endothelial cells are often thought to be
geneticallynormal,workbyHidaetal.hasdemonstratedthat
mouse endothelial cells harvested from tumor xenografts are
aneuploid and have abnormal centromeres [124]. Perhaps
related to this cytogenetic abnormality, tumor endothelial
cellsexpressspeciﬁcmoleculesthatareabsentorexpressedat
amuchlowerlevelsonendotheliuminnormalnoncancerous
tissue. Thus, the tumor vasculature is an attractive subject
for imaging with targeted MB and US [125, 126]. The list
of potential target molecules selective for tumor vasculature
is growing and includes growth factor receptors, integrins,
ephrins, endoglin, tumor endothelial markers (TEMs), and
markers of cell stress (see Table 1 at supplementary material
available at 10.1155/2010/652320).
The development of surrogate markers of pathological
angiogenesis to monitor the response of patients to antian-
giogenic therapy is of critical importance if antiangiogenic
strategies are to be a viable modality for cancer therapy.
Contrast US using targeted MB can be an eﬃcient tool
to monitor the expression of surface markers by tumor
endothelial cells. This strategy can be used to visualize tumor
blood vessels and in addition can follow the expression level
of markers that are known to be altered by antiangiogenic
therapy. VEGFR2 is a commonly used marker of vascular
endothelial cells and has been used by multiple groups as a
molecular target for MB. Animal models of angiosarcoma,
glioma, and breast cancer showed that VEGFR2 targeted MB
enhanced US imaging in evaluation of tumor angiogenesis
[127, 128]. Recently, our group evaluated vascular response
to antiangiogenic and chemotherapy in mouse models of
pancreatic cancer using MB targeted against VEGFR2, the
VEGF:VEGFR complex, and endoglin [20]. Using three
diﬀerent formulations of tumor vessel speciﬁc MB and US,
we were able to noninvasively monitor vascular function
of subcutaneous and orthotopic pancreatic tumors in mice.
We found that targeting to VEGFR2, endoglin, or the
VEGF:VEGFR complex was speciﬁc for tumor vasculature as
there was no signal enhancement in nontumor tumor tissue.
Further, we found that anti-VEGF therapy or treatment
with gemcitabine reduced the expression of the molecular
targets bound by targeted MB. Our contrast US intensity
datacorrelatedwithimmunohistochemicalanalysisoftumor
samples, providing the ﬁrst indication that targeted MB
could be used to follow expression of a cell surface target.
Additionally, these studies also validated that gemcitabine
can eﬀect endothelial cells in tumors. Other groups have
since conﬁrmed our ﬁndings using targeted MB to image
the response of tumor vessels to the therapy [129]. These
data and the work of others [130–133] that conclusively
demonstrate the utility of contrast US using targeted MB
support the clinical evaluation of such strategies as a method
for following response to antiangiogenic therapy in cancer
patients.
6. Toxicities of AntiangiogenicTherapies
VEGF signaling is involved in many normal physiologic
processes such as hemostasis, vascular homeostasis and
integrity, and the maintenance of endothelial function
in kidney glomeruli [134]. Following the introduction of
bevacizumab into the clinic, toxic side eﬀects became
apparent. The most common side eﬀects of bevacizumab
and other antiangiogenic agents are hypertension (3–36 %
of patients) and proteinuria (21–64 % of patients) [135].
Although the exact pathophysiological mechanism is not
yet fully understood, there is evidence coming from both
animal and clinical models, that bevacizumab increases
the risk of renal thrombotic microangiopathy [136]. It has
been shown in animal models that after binding to VEGF,
bevacizumab-VEGF immune complexes can be deposited
in the glomerular basement membrane contributing to the
development of both proteinuria and hypertension [137].
Bevacizumab has also been shown to increase the incidence
of hemorrhagic and thrombotic events in cancer patients.
One of the most serious side eﬀects observed in lung cancer
patients are hemoptysis and pulmonary hemorrhage. In
a phase II clinical trial, NSCLC patients with squamous
histology were at a higher risk of developing fatal bleeding,
that was most likely related to tumor necrosis and proximity
of tumor to the large vessels [138]. Based on this observation
bevacizumab is not recommended for squamous NSCLC.
In addition, bevacizumab is not recommended for patients
with pre-existing conditions that may predispose for either
thrombotic or hemorrhagic events (e.g., brain metastases).
Bevacizumab can also potentiate the incidence of side eﬀects
thatarespeciﬁctochemotherapytreatmentlikeneutropenia,
infections, and thrombocytopenia [139]. There have also
been reports of potentially serious toxicities such as nasal
septum perforation, reversible posterior leukoencephalopa-
thy syndrome (severe hypertension, cortical blindness, and
seizures) or osteonecrosis of the jaw, although these events
are very rare [140–142]. TKIs have a unique toxicity proﬁle
and are more commonly associated with rash due to
blocking EGFR activity and gastrointestinal symptoms like
nausea, diarrhea due to the administration of the drug.
Hypertension is the predominate toxicity associated with
sorafenibandsunitinibtreatmentduetotheirantiangiogenic
speciﬁcities [143]. Endothelial cell production of nitric oxide
andprostacyclinisrequiredformediating vasodilatationand
controlling blood pressure. These mediators are stimulated
by VEGF-induced VEGFR2 signaling, which is blockedJournal of Oncology 7
by sorafenib and sunitinib treatment. Further, TKIs have
recently been reported to increase patient risk of bleeding
events due to interruption of VEGF-mediated vascular
homeostasis [144].
7. FutureDirections
Despite the modest survival beneﬁts observed in clinical
practice, antiangiogenic therapy remains an attractive con-
cept.Onlyﬁveyearshavepassedsincetheﬁrstantiangiogenic
drug was approved by the FDA for a clinical use. Although
we have learned important lessons about this new class of
cancer drugs, many questions still remain. The multitude
of ongoing clinical trials testing both the new agents and
diﬀerent combinations of agents with already established
clinical beneﬁts, may shed light on multiple questions
regarding antiangiogenic therapy [145]. Better selection of
patients, including the therapeutic schedule of antiangio-
genic therapy (i.e., adjuvant versus palliative), monitoring of
clinicalresponse, andbettertoxicity proﬁleofantiangiogenic
drugs are among the most important clinical aspects that the
ongoing clinical trials will address. In addition, intrinsic and
acquired resistance of tumors to antiangiogenic therapies
is a growing concern in the clinic, as most patients fail
to show sustained beneﬁt with continuous therapy [146].
There are many possible mechanisms of resistance to
antiangiogenic therapy that are being actively investigated.
One possibility is the activation of alternative molecular
pathways resulting in ongoing angiogenesis in response
to the presence of a selective inhibitor (e.g., ﬁbroblast
growth factor (FGF), interleukin-8, ephrins, angiopoietins,
SDF-1 pathway activation, and increased VEGF expression
following epidermal growth factor blockade) [147–149].
Also, resistance has been linked to an unresponsiveness of
pericyte-covered tumor vessels to antiangiogenic therapies
[150, 151], and to the hypovascularity and low levels of
de novo angiogenesis characteristic of some tumors (e.g.,
pancreatic cancer) [152]. Although antiangiogenic therapies
have entered into clinical practice, we still lack a reliable
marker(s) of treatment eﬃcacy. Studies on noninvasive
marker(s) such as blood levels of circulating growth factors,
cytokines and/or endothelial progenitor cells gave mixed
results and are not validated at the present time for a clinical
use [153]. Future studies that involve complex proteomic-
based analysis may help to ﬁnd a noninvasive way to not only
monitor the eﬀects by also to better select patients who may
beneﬁt from antiangiogenic therapies.
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